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Abstract
In this preliminary study we show that in 2008, 3 years after antiretroviral therapy was introduced into the
Karonga District, Malawi, a greater than expected number of drug-naive individuals have been infected with
HIV-1 subtype C virus harboring major and minor drug resistance mutations (DRMs). From a sample size of 40
reverse transcriptase (RT) consensus sequences from drug-naive individuals we found five showing NRTI and
four showing NNRTI mutations with one individual showing both. From 29 protease consensus sequences,
again from drug-naive individuals, we found evidence of minor DRMs in three. Additional major and minor
DRMs were found in clonal sequences from a number of individuals that were not present in the original
consensus sequences. This clearly illustrates the importance of sequencing multiple HIV-1 variants from indi-
viduals to fully assess drug resistance.
Malawi has an HIV-1 prevalence of around 12%(UNAIDS 2009). Although the prevalence is higher in
urban areas, 80% of the population lives in rural areas, and the
epidemic in these areas remains a concern and access to
treatment more problematic. Over 200,000 people in Malawi
have been on antiretroviral therapy (ART) and approximately
147,000 are currently on treatment.1 Around 95% of them are
on first-line therapy, 4% are on alternative first-line therapy,
and less than 1% are on second-line therapy.1 A fundamental
concern of antiretroviral drug delivery programs is the
avoidance of the development of widespread drug resistance.
Drug resistance mutations (DRMs) have been primarily
characterized for subtype B, which is predominant in Amer-
ica, Europe, and Australia where ART has been available for a
decade and half, and where approximately 10% of new HIV
infections are with drug-resistant isolates.2 Fewer studies
have characterized drug resistance in subtype C, which is
responsible for more than 50% of worldwide infections.
However, minor mutations associated with drug resistance
have been reported in HIV-1 subtype C-infected drug-naive
patients in a number of African locations including Malawi,
and the percentage of drug-naive individuals harboring HIV
with DRMs thus far has been shown to vary between 2% and
10%.3–6 Further characterization of drug resistance mutations
in subtype-C HIV-1 and monitoring for transmission of drug-
resistant strains are extremely important both given the more
recent wide-scale availability of ART in countries in which
subtype C is predominant, and as the prevalence of non-B
HIV-1 increases in countries in which antiretroviral drugs are
widely used.
Karonga District is the northernmost district of Malawi and
HIV-1 subtype C has been reported to be the most predomi-
nant subtype in this District.7 ART drugs were introduced in
Malawi first in the context of prevention of maternal-to-child
transmission (PMTCT) through antenatal clinics (using a
mother and child nevirapine regime, which is ongoing). Full
ART first became available at public clinics in the two major
cities in Malawi in 2003, in the regional capital in 2004, and at
Karonga district hospital in June 2005, at which time Karonga
residents who had been seeking care outside the district were
transferred to local services. ART delivery has been largely
based on clinical assessment with CD4 counting becoming
available in January 2008 at one clinic. Viral load assessment
and routine drug resistance testing are not available and the
baseline genotype of the genes, which are the targets for ART,
are unknown. The objective of this study was to investigate
the presence of polymorphisms associated with drug resis-
tance found in the reverse transcriptase (RT) and protease
(PR) regions and to explore the intrapatient diversity of HIV-1
in these gene regions at a timewhenmost individuals seen are
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drug naive and transmission of drug resistance from ART-
treated individuals should be uncommon.
DNA was extracted from blood samples from 71 individ-
uals living in Karonga District, Malawi using the QIAamp
DNA Blood Mini Kit (QIAGEN Ltd). Extracted DNA was
subjected to nested polymerase chain reaction (PCR) ampli-
fication of the HIV-1 PR and RT genes employing the primers
previously described.6 The PCR mixture contained 1.5mM
MgCl2, 1.5 units of Taq (Roche Expand High Fidelity PCR
system), 0.8mM each dNTP, and 5pM primers (Eurofins
MWG Operon). The cycling conditions were as follows:
‘‘hotstart’’ at 988C for 1min, primary denaturation at 948C for
2min followed by 35 cycles with 1min denaturation at 948C,
1min annealing at 428C, 4min extension at 728C, and final
extension for 7min at 728C. For each gene region from 10
samples two PCR amplifications were pooled and themixture
cloned using the TOPO Cloning Kit (Invitrogen). Colony PCR
and sequencing were carried out on 30 colonies per sample.
Sequences obtained were edited in SeqMan (Lasergene,
DNASTAR, Inc) and aligned using MacClade 4.0 (Sinauer
Associates).
Preliminary phylogenetic analyses were first carried out to
identify the subtype status of all sequences generated. Sub-
sequently all consensus and clonal sequences that were sub-
type Cwere assembled intomultiple alignments for each gene
region using MacClade 4.0. Phylogenetic trees were re-
constructed using the LANL (www.hiv.lanl.gov/content/
index) subtype C ancestral sequence as outgroup under the
GTRþ gamma model of DNA substitution implemented
RAxML 7.0.38 with all parameters optimized by RAxML.
Confidence levels in the groupings in the phylogeny were
assessed using 1000 bootstrap replicates as part of the RAxML
phylogeny reconstruction. To evaluate the effect of DRMs on
clustering of individual sequences, analyses were also carried
out with all sites showing the presence of DRMs removed.
Sequences were submitted for analysis of DRMs to the Stan-
ford Database (http://hivdb.stanford.edu).
Of the 71 DNA samples, amplification and sequencing
were successful from 62 for RT and from 53 for PR. Three RT
and six PR sequences were excluded from analysis because of
poor quality and four individuals were infected with non-
subtype C virus (no DRMs were present in these non-C se-
quences). For both gene fragments from subtype C strains
phylogenetic analyses with and without DRMS present
showed identical tree topologies indicating that sharing
the same DRM was not, by itself, responsible for individual
sequences clustering together. Figure 1 shows the relation-
ships between sequences with DRMS included.
RTsequences included sequences from 40 individuals who
were drug naive and from 17 who had been on ART. None of
the drug-exposed individuals showed any DRMs, however,
five (5/40) drug-naı¨ve individuals showed nucleoside reverse
transcriptase inhibitor (NRTI) resistance mutations and four
(4/40) showed non-NRTI (NNRTI) resistance mutations with
both types of drug resistance mutations found in one indi-
vidual (Table 1). The NRTI mutations foundwere V75LV (one
individual) and V118I (four individuals) with five NNRTI
mutations identified (A98G, K101Q, V106LV, E138A, and
G190R) (Table 1). V118I occurs in*2% of untreated persons
infected with subtype C and with increased frequency in
persons receiving multiple NRTIs.9 It causes low-level resis-
tance to 3TC and possibly to other NRTIs when present with
other mutations.10 This was the only mutation found in both
previous studies of drug resistance mutations in Malawi, be-
ing present in 4 of 21 individuals studied by Petch et al.3 and
15 of 96 individuals with confirmed virologic failure by
Hosseinipour et al.11 Of the other drug resistance mutations
found K101Q minimally reduces susceptibility to each of the
NNRTIs, whereas mutation at position 75 (V75T/M/A/I) is
associated with reduced NRTI susceptibility (http://hivdb
.stanford.edu).
According to the Stanford database G190R is a highly un-
usual mutation and is flagged as an NNRTI resistance mu-
tation. Little seems to be known about the effects of this
mutation as yet in subtype C but G190A/S/E/Q/T/V/C are
NNRTI resistance mutations. Similarly, although V106A
causes high-level resistance to NVP and DLV and low to in-
termediate resistance to EFV, V106L is a rare polymorphism
and its association with NNRTI resistance is less clear; E138A
is responsible for decreased ETR response and A98G re-
duces NVP susceptibility by two- to threefold (http://hivdb
.stanford.edu).
Cloning was successful for seven samples (Table 2). From
individuals whose consensus sequence showed neither NRTI
nor NNRTI drug resistance mutations, none of the clonal
sequences generated showed drug resistance mutations
(Table 2). All cloned sequences obtained from individual
53733 contained the NRTI V118I mutation that was found in
the consensus sequence and one clonal sequence showed an
additional L74K NRTI-resistant mutation. The consensus se-
quence retrieved from individual 54117 showed a G190R
(NNRTI) mutation and also had four stop codons at positions
71, 88, 212, and 239 (according to HXB2 RT gene). All clones
obtained from this individual showed the same four stop
codons and the same G190R mutation. This study utilized
proviral DNA to generate RT and PR sequences due to the
Table 1. Mutations Associated with Antiretroviral
Drug Resistance Found in Consensus Sequences from
HIVþ Individuals from Karonga District Malawia
Reverse transcriptase
Sample no. NRTI NNRTI Protease
Drug exposed
54302 No sequence T74S
53972 No sequence L76S
53278 None None T74S
53974 None None L10V, T74S
Drug naı¨ve
54208 No sequence T74S
53394 V118I None None
53436 V118I None No sequence
53733 V118I None No sequence
53900 V118I None None
54434 V75LV V106LV None
53977 None None T74S
54023 None K101Q, E138A T74S
54117 None G190R None
54357 None A98G No sequence
aMutations involved in resistance to NRTI and NNRTI drugs and
minor mutations involved in resistance to protease inhibitors are
shown. The four shown in bold were previously drug exposed prior
to enrolling in the study.
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FIG. 1. Maximum likelihood trees generated from reverse transcriptase (a) and protease (b) genes from HIV-1-positive
individuals from Malawi. Branches in color represent sequences from multiple clones of different individuals. Branches in
bold are those showing drug resistance mutations. The numbers on the branches are bootstrap values. *(a) Two consensus
sequences showing the presence of drug resistance mutations grouping together with high support. *(b) Consensus sequences
from a husband and wife pair that group together with high bootstrap support.
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difficulty of working with RNA in this context (i.e., getting
samples from a large population study in rural Africa). HIV-1
with a G–A hypermutation at positions 88 and 212 has pre-
viously been found in resting CD4 cells and the resulting
DNA is reported to be degraded or defective.12,13 It is possible
that the plasma of this individual would yield functional HIV-
1. It is also possible that the individual may be infected with a
defective virus and that this might affect disease progression.
The phylogenetic relationships of the RT sequences from
most individuals were straightforward with both the clonal
and consensus sequences grouping together in monophyletic
groups, with high bootstrap support (Fig. 1a). The clones and
the consensus sequence from 53733 appear to be ancestral to
the virus infecting individual 53900 with both of these indi-
viduals infected with viral strains containing the same NRTI
DRM (V118I). There is no known epidemiological link be-
tween these individuals. The laboratory work on these sam-
ples was carried out by different people and therefore
contamination is not likely in this case. Of the individuals for
whom the PCR products were not cloned there is only one
instance of clustering of sequences containing DRMs with
high bootstrap support (see the asterisk in Fig. 1a). One of
these individuals is a male and the other is a female. These
individuals are in the same reporting group and thusmay live
geographically close together.
Of 45 subtype C protease sequences, 16 were from drug-
exposed individuals and 29 were from drug-naive individu-
als. Seven consensus sequences showed minor PI mutations
including three from drug-naive individuals (Table 1). Clon-
ing was successful for eight samples, three for which the
consensus had shown minor resistance sites and five for
which the consensus showed no drug resistance mutations.
Three drug-exposed individuals (53278, 54302, and 53974)
showed minor PR resistance mutations in clonal sequences
that were not seen in the consensus sequences, whereas 53278
also showed evidence of major PR resistance mutations in the
sequenced clones (Table 3). Furthermore, this pattern was
repeated among the drug-naive individuals with major and
minor DRMs present in clones that were not present in the
consensus sequence (Table 3). Clones of 53278 showed major
mutations D30N, M46I, and I84T. D30N causes high-level
resistance to NFV and potential low-level resistance to ATV.
M46I decreases susceptibility to IDV, NFV, FPV, LPV, and
ATV when present with other mutations. I84V causes inter-
mediate to high-level resistance to various PIs. Minor muta-
tions at position 10 (L10I/V/F/R/Y) are associated with
Table 2. Summary of Amino Acid Diversity in Multiple Sequences Retrieved from Individuals
Showing Evidence of NRTI and NNRTI Resistance Mutations in the Original Consensus
Sequence and from Those That Did Nota
Mutation in original sequence
Sample no. NRTI NNRTI
Number of cloned
sequences obtained
NRTI mutations
found in clones
NNRTI mutations
found in clones
53277 None None 1 None None
53213 None None 27 None None
53218 None None 26 None None
None
53889b None None 27 None None
53733 V118I None 18 L74K, V118I None
53900 V118I None 24 V118I None
54117c None G190R 20 None G190R
aDrug-exposed individuals are in bold.
bConsensus sequence was different from each of the clones.
cAll clones and consensus contained four stop codons.
Table 3. Summary of Amino Acid Diversity in Multiple Sequences Retrieved from Individuals
Showing Evidence of Protease Inhibitor Resistance Mutations in the Original Consensus
Sequence and from Those That Did nota
Mutation in original sequence
Sample no. Major Minor
Number of cloned
sequences obtained
PI resistance major
mutations found in clones
PI resistance minor
mutations found in clones
53278 None T74S 14 D30N, M46I, I84T G48R, T74S
53354 None None 9 None None
53974 None L10V, T74S 29 None L10V, G48R, T74S
54023 None T74S 25 None M46T, T74S
53394 None None 28 None None
53431 None None 30 None None
53843 None None 30 None None
54094 None None 23 I47M None
aDrug-exposed indivudals are in bold.
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resistance to most PIs when present with other mutations and
mutation at this site occurs in 5–10% of untreated persons
including subtype C-infected individuals in Africa.4,5,11,14
Mutation at position 74 (T74S) is associated with reduced
NFV susceptibility whereas mutation at position 76 (L76V)
reduces susceptibility to FPV, IDV, LPV, and DRV and in-
creases susceptibility to SQV, ATV, and TPV.14,15
For most individuals phylogenetic relationships between
the sequences were uncomplicated; however, while 10 clones
and the consensus sequence from individual 53278 clustered
closely and all showed the T74Sminor PI mutation, sequences
of three variants clustered together in the tree with sequences
retrieved from a different individual with whom she has no
known epidemiological links (Fig. 1b) rather than with other
53278 sequences. These three sequence variants were those
that showed major PR inhibitor resistance mutations. Fur-
thermore, none of these three variants showed the original
T74S mutation but did show another minor PI mutation
(G48R). One additional clone sequence was found clustering
with clonal sequences from another female, 54023, again with
whom she had no known link.
This work clearly shows the presence of both NRTI and
NNRTI drug resistance mutations and the presence of minor
and major PR resistance mutations in a number of drug-naive
individuals in rural Malawi in 2008 3 years after ART became
widely available in the district. We have also shown the
importance of sequencing multiple HIV-1 variants from indi-
viduals to fully assess drug resistance, as a number of indi-
viduals have shown major and/or minor drug resistance
mutations in sequenced clones that were not present in the
consensus sequences. Sequencingmultiple clones of RT and PR
from 16 individuals showed that one of them (female, aged 52,
53278 in Fig. 1b) was dual infected and showed evidence of
being infected with viruses containing DRMs. The dual infec-
tion was confirmed by sequencing of multiple clones of the gag
gene as part of another project, which showed a similar pattern
of multiple lineages for this individual (Seager, unpublished).
In terms of identifying possible transmission events involving
HIV-1 with DRMs, apart from the dually infected individual
mentioned above, there are very few cases of clustering of
sequences from individuals with DRMS.
Our analyses showed that the presence of DRMs alone was
not responsible for the pattern of relationships shown on the
trees indicating common ancestry rather than convergence.
However, given the short length of gene fragments used to
explore drug resistance and in many cases having sequence
evidence from only one gene, such results are not reliable
reports of transmission and sequencing of additional loci is
underway to confirm transmission in each case.
The presence of drug-resistant mutations in drug-naive
individuals may prevent successful treatment of certain in-
dividuals. This knowledge may also inform policymakers in
planning future therapy strategies as this indicates that
additional therapy combinations may be required. Although
antiretroviral drugs were made more widely available in
Karonga District in June 2005, prior to this NVPwas available
for the PMTCT in antenatal clinics and full ART would have
been available to a number of individuals elsewhere in
Malawi in 2002. Thus, it is also possible that some individuals
assumed to be drug naı¨ve did not disclose (or in the case of
PMTCT were not aware of ) ART exposure, and did not
appear in the ART study cohorts. Furthermore, the presence
of DRMs in drug-naive persons may represent natural poly-
morphisms and may not be suggestive of transmission of
DRMs. The impact of such natural polymorphisms on the
development of drug resistance in those people at com-
mencement of ART is unknown and such individuals need to
be monitored. Indeed the impact of such polymorphisms on
the HIV-1 subtype C-infected population and the speed of
more widespread drug resistance are also unknown. There-
fore it may be important to further examine some of the in-
dividuals and mutations found during this study in view of a
long-term treatment strategy in the district.
Sequence Data
All sequences have been deposited into GenBank, accession
numbers HQ159410–HQ159841, and alignments employed in
this work are available from the authors on request.
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